Upfront consolidation treatment with (131)I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma

IMPORTANCE: (131)I‐metaiodobenzylguanidine ((131)I‐mIBG) has a significant targeted antitumor effect for neuroblastoma. However, currently there is a paucity of data for the use of (131)I‐mIBG as a “front‐line” therapeutic agent in those patients with newly diagnosed high‐risk neuroblastoma as part...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jianhua, Cheng, Frankie WT, Leung, Alex WK, Lee, Vincent, Yeung, Eva WM, Ching Lam, Hoi, Cheung, Jeanny, Lam, Grace KS, Chow, Terry TW, Yan, Carol LS, Kong Li, Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520103/
https://www.ncbi.nlm.nih.gov/pubmed/33150310
http://dx.doi.org/10.1002/ped4.12216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520103/
https://www.ncbi.nlm.nih.gov/pubmed/33150310
http://dx.doi.org/10.1002/ped4.12216

Ejemplares similares